Buy & Sell Sezzle Inc (SEZL) – Sezzle Inc Price Today
Key Stats
- $5.49BMarket Cap
- TechnologySector
- -19.97%3M Drawdown
- $5.52BEnterprise Value
- -Dividend Yield
- 90% Buy | 10% SellTrading Activity
- 6 daysTypical Hold Time
Sezzle Inc (SEZL) is currently valued at a market capitalization of $5.49B, with an enterprise value of $5.52B. Over the past 52 weeks, Sezzle Inc has traded between a low of $50.97 and a high of $182.16, highlighting its annual price range. Over the past three months, Sezzle Inc has recorded a drawdown of -19.97%, reflecting recent price volatility. On average, investors hold Sezzle Inc for approximately 6 days, indicating typical investor behavior on the platform.
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Most Recent News
Tourism surges at Hengdian World Studios as Pursuit of Jade tops global C-drama charts.
Hengdian World Studios saw a major spike in visitors after the Chinese drama Pursuit of Jade, filmed mostly at the studio, topped international streaming charts and search volumes in 15 countries. During the May holiday, over 80,000 tourists visited ...

Global sputtering equipment market to reach $4.19B by 2035, driven by semiconductor and solar industry growth.
The global sputtering equipment market is projected to grow from USD 2.41 billion in 2025 to USD 4.19 billion by 2035, at a CAGR of 5.83%. Growth is fueled by rising demand for high-performance semiconductors, flat panel displays, and photovoltaic so...

Japan approves Sanofi's Sarclisa subcutaneous formulation for multiple myeloma treatment
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
